Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -858,281 | -886,116 | -761,497 | -490,874 | -410,108 |
| Depreciation Amortization | 74,435 | 54,368 | 15,248 | 11,898 | 15,130 |
| Accounts receivable | -56,236 | -24,238 | 15,242 | -10,668 | -15,036 |
| Accounts payable and accrued liabilities | 143,732 | 92,354 | 74,835 | 26,629 | 10,098 |
| Other Working Capital | -12,701 | 402,381 | 45,099 | -2,902 | 17,219 |
| Other Operating Activity | 94,090 | 82,824 | 48,457 | 83,131 | 74,996 |
| Operating Cash Flow | $-614,961 | $-278,427 | $-562,616 | $-382,786 | $-307,701 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -333,957 | -300,521 | 414,657 | -306,152 | 357,148 |
| PPE Investments | -70,361 | -140,156 | -126,887 | -104,209 | -64,557 |
| Purchase Of Investment | -25,900 | N/A | -14,825 | 120,000 | -150,000 |
| Sale Of Investment | N/A | 30,000 | N/A | N/A | N/A |
| Other Investing Activity | -5,300 | -7,000 | 0 | 0 | 0 |
| Investing Cash Flow | $-435,518 | $-417,677 | $272,945 | $-290,361 | $142,591 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 200,000 | 0 | N/A | N/A | 150,000 |
| Debt Repayment | 0 | N/A | 0 | -120,000 | N/A |
| Common Stock Issued | 299,982 | 853,184 | 65,470 | 1,244,891 | 28,428 |
| Common Stock Repurchased | N/A | N/A | N/A | N/A | -596 |
| Other Financing Activity | 494,997 | -30,000 | 0 | 0 | 0 |
| Financing Cash Flow | $994,979 | $823,184 | $65,470 | $1,124,891 | $177,832 |
| Exchange Rate Effect | 4,918 | -83 | N/A | N/A | N/A |
| Beginning Cash Position | 549,628 | 422,631 | 646,832 | 195,088 | 182,366 |
| End Cash Position | 499,046 | 549,628 | 422,631 | 646,832 | 195,088 |
| Net Cash Flow | $-50,582 | $126,997 | $-224,201 | $451,744 | $12,722 |
| Free Cash Flow | |||||
| Operating Cash Flow | -614,961 | -278,427 | -562,616 | -382,786 | -307,701 |
| Capital Expenditure | -70,361 | -140,156 | -126,887 | -104,209 | -64,557 |
| Free Cash Flow | -685,322 | -418,583 | -689,503 | -486,995 | -372,258 |